Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Open Access
- 31 July 2023
- journal article
- research article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 21 (3) , 339-352
Abstract
Background/Aims: As the characteristics of inflammatory bowel disease (IBD) differ between Asians and Westerners, it is necessary to determine adequate therapeutic strategy for Asian IBD patients. We evaluated the current treatment of IBD in Asian countries/regions using a web-based survey. Methods: The Korean Association for the Study of Intestinal Diseases conducted a multinational web-based survey for current IBD care in Asia between September 16, 2020, and November 13, 2020. Results: A total of 384 doctors treating IBD patients from 24 Asian countries/regions responded to the survey. Anti-tumor necrosis factor (TNF) agents, anti-integrins, and anti-interleukin-12/23 agents were available for use by 93.8%, 72.1%, and 70.1% of respondents in Asian countries/regions. Compared with a previous survey performed in 2014, an increased tendency for treatment with biologics, including anti-TNF agents, was observed. In the treatment of corticosteroid-refractory acute severe ulcerative colitis, 72.1% of respondents chose anti-TNF agents, followed by tacrolimus (11.7%). In the treatment of corticosteroid-refractory Crohn’s disease, 90.4% chose anti-TNF agents, followed by thiopurines (53.1%), anti-interleukin-12/23 agents (39.3%), and anti-integrin agents (35.7%). In the treatment of Crohn’s disease patients refractory to anti-TNF agents, the most preferred strategy was to measure serum levels of anti-TNF and anti-drug antibodies (40.9%), followed by empiric dose escalation or shortening of dosing intervals (25.3%). Conclusions: Although there were some differences, treatment strategies for patients with IBD were mostly similar among Asian doctors. Based on the therapeutic outcomes, it is necessary to identify the most appropriate therapeutic strategy for Asian IBD patients.Keywords
This publication has 47 references indexed in Scilit:
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2016
- Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2ndAsian Organization for Crohn's and Colitis (AOCC) meeting in SeoulIntestinal Research, 2016
- Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populationsNature Genetics, 2015
- A Questionnaire-Based Survey on the Diagnosis and Management of Inflammatory Bowel Disease in East Asian Countries in 2012Digestion, 2014
- Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population‐based studyJournal of Gastroenterology and Hepatology, 2013
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialThe Lancet, 2012
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2010
- Consensus on the management of inflammatory bowel disease in China in 2007*Journal of Digestive Diseases, 2008
- Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of GastroenterologyCanadian Journal of Gastroenterology and Hepatology, 2005
- European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatmentGastroenterology, 1984